DuPont opens new biopharma tubing manufacturing plant in Cooper River, South Carolina; plant to add additional extrusion capacity over the next two years, expand Liveo Healthcare customer base with additional supply in the medium term

Sample article from our Tissue & Hygiene

WILMINGTON, Delaware , June 2, 2022 (press release) –

Expansion of biopharma processing tubing manufacturing capabilities with state-of-the-art infrastructure will support customer growth

DuPont (NYSE:DD) today announced the opening of its new DuPont™ Liveo™ Healthcare manufacturing site in Cooper River, South Carolina, to help better serve customers worldwide.

The site, located in Berkeley County, will be operated using the same quality standards as DuPont’s Healthcare Industries Materials Site, the company’s longstanding biopharmaceutical manufacturing site in Hemlock, Michigan. The Cooper River site will bring additional extrusion capacity online over the next two years to serve strategic customers in the short term and expand its Liveo™ Healthcare customer base with additional supply in the medium term.

“The biopharma processing manufacturing investment at Cooper River is a key milestone in our growth strategy; it supports our customers’ expansion and contributes to business continuity,” said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino. “We’re committed to investing in our healthcare business, and our recent expansions help us offer a highly reliable and sustainable product supply.”

DuPont™ Liveo™ Healthcare is also expanding its manufacturing footprint regionally to support customers locally, which will help alleviate supply pressure and allow customers to grow in their respective markets. In the second half of 2022, the company expects to add biopharma silicone tubing capacity in China to serve the fast-growing customers in the region.

“Through a strong, close collaboration between our DuPont team and our contractor partners, construction of the new Cooper River site was completed in 18 months, without a single safety incident,” said Bill Alexander, Cooper River site and unit leader for the DuPont™ Liveo™, and MOLYKOTE® plants. “The site has enabled the creation of 25 positions at start-up, with an additional 25 positions expected to be created as we ramp up operations over the next two years,” added Alexander.

"For more than fourteen years, DuPont Cooper River has continued to diversify and reinvest in new products ensuring the viability of this Berkeley County facility. Life sciences and biotechnology innovation is a growing sector with an $11 billion annual economic impact and over 40,000 jobs in the State of South Carolina. We thank DuPont for their commitment to this community and for creating more high-paying jobs for the local workforce," said Kristen O. Lanier, Berkeley County Economic Development Director.

In 2021, the DuPont Cooper River site expanded to include manufacturing of DuPont™ MOLYKOTE® Specialty Lubricants.

As a trusted partner in the healthcare processing industry, DuPont has developed a leadership position within the industry by building upon more than seven decades of foundational capabilities that serve the highly regulated biopharmaceutical market. With these recent investments, DuPont is committed to serving the healthcare market and its customers more than ever, offering high-quality, high-performance solutions; application and material science expertise; and strong regulatory support to address healthcare customers’ specific needs and challenges.

About DuPont™ Liveo™ Healthcare Solutions
DuPont™ Liveo™ is a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing and pharmaceutical solutions. DuPont high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information can be found at liveo.dupont.com.

About DuPont Electronics & Industrial
DuPont Electronics & Industrial is a global supplier of new technologies and performance materials serving the semiconductor, circuit board, display, digital and flexographic printing, healthcare, aerospace, industrial, and transportation industries. From advanced technology centers worldwide, teams of talented research scientists and application experts work closely with customers, providing solutions, products and technical service to enable next-generation technologies.

About DuPont
DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at http://www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

Overview

On November 2, 2021, DuPont announced it has entered definitive agreements to acquire Rogers Corporation (“Rogers”), (the “Intended Rogers Acquisition”). On January 25, 2022, Rogers shareholders approved the transaction. Closing, is expected by the end of the second quarter 2022, subject to regulatory approvals and customary closing conditions.

On February 18, 2022, DuPont announced that it has entered into definitive agreements to divest a majority of its Mobility & Materials segment, excluding certain Advanced Solutions and Performance Resins businesses, to Celanese Corporation (“Celanese”), (the “M&M Divestiture”). Closing is expected around the end of 2022, subject to regulatory approvals and customary closing conditions.

The Company also announced on February 18, 2022 that its Board of Directors has approved the divestiture of the Delrin® acetal homopolymer (H-POM) business. In addition to the entry into definitive agreements, the Company anticipates that the closing of the sale of Delrin® would be subject to regulatory approvals and other customary closing conditions, (the “Delrin® Business Divestiture” and together with the M&M Divestiture, the "M&M Divestitures”).

Cautionary Statement Regarding Forward Looking Statements

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the M&M Divestiture to Celanese, including (x) any failure to obtain necessary regulatory approvals, anticipated tax treatment or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies could impact the value, timing or pursuit of the proposed transaction, and (z) risks and costs and pursuit and/or implementation, timing and impacts to business operations of the separation of business lines in scope for the M&M Divestiture to Celanese, (ii) the timing and outcome of the Delrin® Business Divestiture, including entry into definitive agreements, and the risks, costs and ability to realize benefits from the pursuit of the Delrin® Business Divestiture; (iii) ability to achieve anticipated tax treatments in connection with mergers, acquisitions, divestitures and other portfolio changes actions and impact of changes in relevant tax and other laws; (iv) indemnification of certain legacy liabilities; (v) risks and costs related to each of the parties respective performance under and the impact of the arrangement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (vi) failure to timely close on anticipated terms (or at all), realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with mergers, acquisitions, divestitures and other portfolio changes including the Intended Rogers Acquisition and the M&M Divestitures; (vii) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to operational and supply chain impacts or disruptions, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geo-political and weather related events; (viii) ability to offset increases in cost of inputs, including raw materials, energy and logistics; and (ix) other risks to DuPont's business, operations; each as further discussed in DuPont’s most recent annual report and subsequent current and periodic reports filed with the U.S. Securities and Exchange Commission. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

# # #

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

05/31/22

Image:

High resolution:
https://dupont.scene7.com/is/image/Dupont/Cooper" target="_blank" >https://dupont.scene7.com/is/image/Dupont/Cooper River_high

Low resolution:
https://dupont.scene7.com/is/image/Dupont/Cooper" target="_blank" >https://dupont.scene7.com/is/image/Dupont/Cooper River_low

Proposed caption:

DuPont opens new biopharma tubing manufacturing site with state-of-the-art infrastructure at Cooper River in the United States

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.